Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

JOURNAL ARTICLE published June 2014 in Investigational New Drugs

Authors: Kevin R. Kelly | Thomas C. Shea | André Goy | Jesus G. Berdeja | Craig B. Reeder | Kevin T. McDonagh | Xiaofei Zhou | Hadi Danaee | Hua Liu | Jeffrey A. Ecsedy | Huifeng Niu | Ely Benaim | Swaminathan Padmanabhan Iyer